Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 3/2022

01-04-2022 | Human Papillomavirus | Letter to Editor

To the Editor: “Complete Resolution of Multiple Warts after a First Dose of the Receptor Interleukin-5 Inhibitor”

Authors: Kissy Guevara-Hoyer, Eduardo de la Fuente-Munoz, Celia Pinedo Sierra, Teresa Robledo, Silvia Sánchez-Ramón

Published in: Journal of Clinical Immunology | Issue 3/2022

Login to get access

Excerpt

The patient was a 42-year-old man with a long medical history of multiple warts on hands, feet, and genital region (> 15 active lesions) since childhood associated with human papillomavirus (HPV), followed in our center since 2010 by the Dermatology department. He had received multiple treatments, as trichloroacetic acid, topical antiviral chemotherapies (imiquimod), cryotherapy, and laser, without response and persistent recurrences. …
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
Metadata
Title
To the Editor: “Complete Resolution of Multiple Warts after a First Dose of the Receptor Interleukin-5 Inhibitor”
Authors
Kissy Guevara-Hoyer
Eduardo de la Fuente-Munoz
Celia Pinedo Sierra
Teresa Robledo
Silvia Sánchez-Ramón
Publication date
01-04-2022
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2022
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01202-4

Other articles of this Issue 3/2022

Journal of Clinical Immunology 3/2022 Go to the issue

Letter to Editor

A Pitfall of Whole Exome Sequencing: Variants in the 5′UTR Splice Site of BTK Causing XLA

Letter to Editor

Activated PI3 Kinase Delta Syndrome Revealed by Vasculitis and Disseminated Toxoplasmosis

Letter to Editor

Vanishing Lymphocytes in a Case of Vanishing Bone Disease

Original Article

Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome

Correction

Correction to: The Immune Deficiency and Dysregulation Activity (IDDA2.1 ‘Kaleidoscope’) Score and Other Clinical Measures in Inborn Errors of Immunity

Original Article

CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits